Why Did SoundHound AI Stock Go Up?
SoundHound AI (NASDAQ:SOUN) has moved higher in recent days, breaking…
Buy
62
INFU Quote, Financials, Valuation and Earnings
Last price:
$8.54
Seasonality move
:
3.56%
Day range:
$8.54 - $8.80
52-week range:
$4.61 - $11.04
Dividend yield:
0%
P/E ratio:
33.08x
P/S ratio:
1.30x
P/B ratio:
3.17x
Volume:
91.7K
Avg. volume:
118.9K
1-year change:
7.59%
Market cap:
$175.9M
Revenue:
$134.9M
EPS (TTM):
$0.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
$36.7M | $0.05 | 8.36% | 39.86% | $14.20 |
|
CATX
Perspective Therapeutics, Inc.
|
$231.1K | -$0.35 | -57.02% | -40.33% | $12.3077 |
|
RMD
ResMed, Inc.
|
$1.4B | $2.72 | 9.18% | 11.75% | $292.33 |
|
VNRX
VolitionRX Ltd.
|
$714.1K | -$0.04 | 227.21% | -28.83% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$30.8M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
$8.65 | $14.20 | $175.9M | 33.08x | $0.00 | 0% | 1.30x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.6700 | $12.3077 | $198.5M | -- | $0.00 | 0% | 181.04x |
|
RMD
ResMed, Inc.
|
$255.35 | $292.33 | $37.3B | 26.13x | $0.60 | 0.89% | 7.15x |
|
VNRX
VolitionRX Ltd.
|
$0.29 | $2.20 | $35.5M | -- | $0.00 | 0% | 19.79x |
|
VTAK
Catheter Precision, Inc.
|
$2.22 | -- | $2.7M | 0.40x | $0.00 | 0% | 10.44x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.62 | $1.50 | $87.1M | 60.99x | $0.00 | 0% | 0.68x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
30.8% | 4.042 | 11.73% | 1.35x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.042 | 1.3% | 8.47x |
|
RMD
ResMed, Inc.
|
12.15% | 0.549 | 2.12% | 1.89x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.723 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | 0.156 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 3.120 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
$20.3M | $3.8M | 6.43% | 9.93% | 10.45% | $8.4M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
RMD
ResMed, Inc.
|
$808.9M | $462.3M | 22.25% | 25.6% | 34.62% | $411.5M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
InfuSystem Holdings, Inc. vs. Competitors
-
Which has Higher Returns INFU or CATX?
Perspective Therapeutics, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -12425.36%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About INFU or CATX?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 64.16%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 360.96%. Given that Perspective Therapeutics, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is INFU or CATX More Risky?
InfuSystem Holdings, Inc. has a beta of 1.680, which suggesting that the stock is 68.01% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.
-
Which is a Better Dividend Stock INFU or CATX?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or CATX?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 33.08x while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.30x versus 181.04x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.30x 33.08x $36.5M $2.3M CATXPerspective Therapeutics, Inc.181.04x -- $209K -$26M
-
Which has Higher Returns INFU or RMD?
ResMed, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of 26.1%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat ResMed, Inc.'s return on equity of 25.6%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M RMDResMed, Inc.60.56% $2.37 $7B -
What do Analysts Say About INFU or RMD?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 64.16%. On the other hand ResMed, Inc. has an analysts' consensus of $292.33 which suggests that it could grow by 14.48%. Given that InfuSystem Holdings, Inc. has higher upside potential than ResMed, Inc., analysts believe InfuSystem Holdings, Inc. is more attractive than ResMed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 RMDResMed, Inc.8 7 1 -
Is INFU or RMD More Risky?
InfuSystem Holdings, Inc. has a beta of 1.680, which suggesting that the stock is 68.01% more volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.876, suggesting its less volatile than the S&P 500 by 12.416%.
-
Which is a Better Dividend Stock INFU or RMD?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 0.89% to investors and pays a quarterly dividend of $0.60 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios INFU or RMD?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are smaller than ResMed, Inc. quarterly revenues of $1.3B. InfuSystem Holdings, Inc.'s net income of $2.3M is lower than ResMed, Inc.'s net income of $348.5M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 33.08x while ResMed, Inc.'s PE ratio is 26.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.30x versus 7.15x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.30x 33.08x $36.5M $2.3M RMDResMed, Inc.7.15x 26.13x $1.3B $348.5M
-
Which has Higher Returns INFU or VNRX?
VolitionRX Ltd. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -862.39%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About INFU or VNRX?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 64.16%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 661.77%. Given that VolitionRX Ltd. has higher upside potential than InfuSystem Holdings, Inc., analysts believe VolitionRX Ltd. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is INFU or VNRX More Risky?
InfuSystem Holdings, Inc. has a beta of 1.680, which suggesting that the stock is 68.01% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.234, suggesting its more volatile than the S&P 500 by 23.404%.
-
Which is a Better Dividend Stock INFU or VNRX?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or VNRX?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 33.08x while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.30x versus 19.79x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.30x 33.08x $36.5M $2.3M VNRXVolitionRX Ltd.19.79x -- $627.3K -$5.4M
-
Which has Higher Returns INFU or VTAK?
Catheter Precision, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of -1037.17%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About INFU or VTAK?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 64.16%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1611.76%. Given that Catheter Precision, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Catheter Precision, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 VTAKCatheter Precision, Inc.0 0 0 -
Is INFU or VTAK More Risky?
InfuSystem Holdings, Inc. has a beta of 1.680, which suggesting that the stock is 68.01% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.392, suggesting its less volatile than the S&P 500 by 239.195%.
-
Which is a Better Dividend Stock INFU or VTAK?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or VTAK?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 33.08x while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.30x versus 10.44x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.30x 33.08x $36.5M $2.3M VTAKCatheter Precision, Inc.10.44x 0.40x $226K -$2.3M
-
Which has Higher Returns INFU or XTNT?
Xtant Medical Holdings, Inc. has a net margin of 6.19% compared to InfuSystem Holdings, Inc.'s net margin of 3.93%. InfuSystem Holdings, Inc.'s return on equity of 9.93% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital INFUInfuSystem Holdings, Inc.55.65% $0.11 $80.2M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About INFU or XTNT?
InfuSystem Holdings, Inc. has a consensus price target of $14.20, signalling upside risk potential of 64.16%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 141.12%. Given that Xtant Medical Holdings, Inc. has higher upside potential than InfuSystem Holdings, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than InfuSystem Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INFUInfuSystem Holdings, Inc.5 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is INFU or XTNT More Risky?
InfuSystem Holdings, Inc. has a beta of 1.680, which suggesting that the stock is 68.01% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.077, suggesting its less volatile than the S&P 500 by 107.701%.
-
Which is a Better Dividend Stock INFU or XTNT?
InfuSystem Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. InfuSystem Holdings, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INFU or XTNT?
InfuSystem Holdings, Inc. quarterly revenues are $36.5M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. InfuSystem Holdings, Inc.'s net income of $2.3M is higher than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, InfuSystem Holdings, Inc.'s price-to-earnings ratio is 33.08x while Xtant Medical Holdings, Inc.'s PE ratio is 60.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for InfuSystem Holdings, Inc. is 1.30x versus 0.68x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INFUInfuSystem Holdings, Inc.1.30x 33.08x $36.5M $2.3M XTNTXtant Medical Holdings, Inc.0.68x 60.99x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Goldman Sachs Going to Go Up?
Shares of financial giant Goldman Sachs (NYSE:GS) have soared by…
How High Will MSTR Stock Go?
After several months of pressure, shares of Bitcoin treasury Strategy…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
59
RGC alert for Jan 23
Regencell Bioscience Holdings Ltd. [RGC] is up 7.31% over the past day.
Buy
76
HYMC alert for Jan 23
Hycroft Mining Holding Corp. [HYMC] is up 9.62% over the past day.
Sell
24
INSP alert for Jan 23
Inspire Medical Systems, Inc. [INSP] is down 1.14% over the past day.
